BaseStation DNA Sequencer

描述(申请人提供)：俄克拉荷马医学研究基金会在大约三年前建立了DNA测序的核心实验室。目前的设施配备了两名熟练的研究助理，并由两台ABI 377 DNA测序仪组成。目前的仪器已经满负荷运行，几乎不足以处理我们基金会内的测序项目数量。因此，这种共用设备对新的MJ Basestation DNA测序仪的请求，每24小时产生数百个序列，比377少动手，将增强我们的测序能力，并为我们在可预见的未来预测的需求提供核心DNA测序支持。 该提案中概述的需要额外测序能力的具体研究项目，涉及V(D)J重排/体细胞突变水平上的免疫球蛋白多样性和粘膜免疫的分子机制；涉及凝血的基本机制，重点是EPCR和蛋白C结构与功能的关系；通过黏附选择调节白细胞的运输，以应对组织损伤；以及阐明自身免疫病的病因。此外，OMRF新建立的微阵列设施，为参与这项提议的许多研究人员提供服务，并进行自己的独立研究项目，产生了对额外DNA测序能力的迫切需求。 因此，这五个研究项目体现了调查人员的不同核心，与提案中描述的其他研究项目一起，代表了DNA测序的需求，预计这些需求将在未来一年超出我们目前的能力。此外，NIH和NSF资助的研究人员都参与了这一申请。这个 在我们目前的DNA测序设施基础上再购买一台测序仪，将对俄克拉荷马医学研究基金会正在进行的研究的数量和质量产生重大影响。

DESCRIPTION (provided by applicant): The Oklahoma Medical Research Foundation established a core laboratory for DNA sequencing approximately three years ago. The current facility is staffed by two skilled research assistants and consists of two ABI 377 DNA sequencers. The current instruments, run at capacity, are barely adequate to deal with the number of sequencing projects within our Foundation. Thus, this shared equipment request for a new MJ BaseStation DNA sequencer, yielding several hundred sequences every 24 hours with less hands on labor than with the 377s, will bolster our sequencing capacity and provide the core DNA sequencing support for our projected needs for the foreseeable future. The specific research projects outlined in this proposal, and requiring additional sequencing capacity, address immunoglobulin diversity at the level of V(D)J rearrangement/somatic mutation and molecular mechanisms of mucosal immunity; fundamental mechanisms involved in blood coagulation with an emphasis on EPCR and protein C structure-function relationships; the regulation of leukocyte trafficking by the adhesion selections in response to tissue injuries; and the elucidation of the etiology of autoimmune disease. Moreover, the newly established Microarray Facility at OMRF, serving many investigators involved in this proposal along with conducting its own independent research projects, has created a critical need for additional DNA sequencing capacity. These five research projects, therefore, exemplify a diverse core of investigators which, in conjunction with the other research projects described in the proposal, represent needs for DNA sequencing that are projected to escalate beyond our current capacity in the coming year. Additionally, both NIH and NSF funded investigators have participated in this application. The acquisition of an additional sequencer to our current DNA Sequencing Facility will have a great impact on the quantity and quality of ongoing research at the Oklahoma Medical Research Foundation.